BeOne Medicines Q1 2026 Financial Results and Business Updates
May 2026
“These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader with sustained competitive advantages in research, clinical development, and manufacturing as well as established leadership in hematology and a rapidly emerging solid tumor pipeline.”
-John V. Oyler, Co-Founder, Chairman, and CEO
Check out the infographic breakdown of our Q1 2026 performance below which highlights strong execution across the hematology and solid tumor franchise and progress across a growing pipeline.
